Clinical Trial · NCT01492192

RGD-PET-CT in Cancer Angiogenesis

Overview

The goal of this clinical research study is to look at 2 new methods of scanning and see whether they can help researchers predict which tumours will respond to drugs that attack tumour blood supply.

Sponsor

University Hospital, Grenoble

Phase

Phase 2

Contacts

Fergus Gleeson (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01492192

Eligibility

Inclusion

Standard staging CT scan performed within 28 days of first research scan
Patient is not lactating or pregnant
Patients considered suitable for therapy with TKI for RCC according to responsible clinician
Patient is able to tolerate and comply with scanning procedure
Patients should have advanced or metastatic RCC confirmed by histological diagnosis
Absence of any psychological, familial, sociological or geographical condition which in the opinion of the Investigator may potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Adequate renal function (creatinine \<1.25xULN)
The patient has not received chemotherapy, radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to recruitment
Measurable tumour according to RECIST v1.1 criteria

Exclusion

Not applicable